ValueGen.AI -- Purpose-Built for HEOR & Market Access
A generative AI platform that automates the most time-consuming tasks across HEOR and market access -- from evidence synthesis and economic modeling to payer strategy and HTA intelligence -- with full traceability and domain-specific reliability scoring.
HEOR
- Economic modeling (CEA, BIM, scenario analysis)
- Automated landscape assessment reports
- Evidence gap identification & prioritization
- Real-world evidence analysis
- ICER / HTA body-specific analyses
- Literature intelligence & evidence synthesis
- Query reliability scoring & validation flags
Market Access
- HTA insights across 7+ markets (NICE, G-BA, ICER...)
- Payer objection handler development
- Value story & payer narrative generation
- Reimbursement landscape intelligence
- Country-specific dossier support
- Competitive intelligence & positioning
- Budget impact & affordability modeling
HEOR
Economic Modeling & Analysis
Cost-Effectiveness Analysis (CEA)
Builds Markov models and decision trees for incremental cost per QALY/LYG. Supports probabilistic sensitivity analysis (PSA), one-way tornado diagrams, and country-specific threshold analyses.
Budget Impact Modeling (BIM)
Estimates net budget impact for payers adopting a new therapy -- accounting for market uptake, patient share, cost offsets, and real-world adherence patterns.
Scenario & Threshold Analysis
Automates scenario modeling across price points, efficacy assumptions, and comparator mixes to identify breakeven ICERs and value-based pricing ranges.
Modeling Capabilities
- Markov cohort & microsimulation
- Monte Carlo probabilistic sensitivity
- Multi-country model adaptations
- Patient-level simulation models
- Lifetime horizon projections
- HEOR-specific reliability scoring
- Early economic modeling & scoping
HEOR
Evidence Generation & Literature Intelligence
Automated Landscape Assessment
Generates comprehensive disease-area landscape reports in 48 hours -- synthesizing HTA reports, guidelines, and published literature across 7+ markets in original language, summarized in English.
Evidence Gap Identification
Algorithmically pinpoints gaps in the evidence base that may affect market access. Ranks gaps by strategic priority to guide clinical study design and real-world evidence collection.
Real-World Evidence (RWE) Analysis
Analyzes payer database data, RWE studies, and observational research to build supplementary evidence packages. Supports comparative effectiveness and adherence analyses.
Deep Research Agent (EvidenceIntel)
An agentic evidence generation system with full traceability. Conducts multi-source retrieval across published literature, HTA databases, and regulatory documents -- with citations and confidence flags.
HEOR
HTA Analytics & Regulatory Intelligence
HTA-Body Specific Analyses
Regulatory Submission Support
Drafts clinical sections of regulatory dossiers (FDA, EMA), value-of-information analyses, and evidence summaries for advisory committee meetings.
Key Value Drivers Identification
Identifies the top clinical, humanistic, and economic value drivers for a therapy -- mapped to HTA body priorities and payer decision criteria.
Methodology aligned with ISPOR GenAI in HTA Task Force guidelines
Market Access
Payer Strategy, Value Messaging & Objection Handling
Payer Value Story Generation
Crafts data-driven value narratives for specific payer audiences -- integrating clinical differentiation, economic offsets, and humanistic outcomes aligned with payer decision criteria.
Objection Handler Development
Identifies anticipated payer objections based on prior HTA decisions, then generates structured Q&A documents with counterarguments on durability, effectiveness, and pricing.
Payer Briefing Notes
Auto-generates concise 1-2 page briefing notes synthesizing clinical evidence, budget impact, and access context -- ready for field teams to use in payer meetings.
Additional Capabilities
- Patient access scheme modeling
- Outcomes-based contract framing
- Country-specific dossier narratives
- AMNOG added-benefit argumentation
- Patient advocacy alignment analysis
- Coverage with evidence development
- RWE for payer negotiation
- Multi-stakeholder objection simulation
Partners
DELIVERABLES
What ValueGen.AI Produces
EXCEL / R
Cost-Effectiveness Model
Markov or decision-tree CEA with PSA, tornado diagrams, ICER outputs, and country-specific threshold analysis.
EXCEL
Budget Impact Model
Payer-level BIM with market uptake, patient share, cost offsets, and scenario toggles.
Web App
Online Interactive Model
Browser-based model with sliders and real-time scenario exploration -- shareable with payers and HTA bodies.
PDF / WORD
Landscape Assessment Report
Comprehensive disease-area landscape generated in 48 hours: HTA history, guidelines, published evidence across 7 markets.
PDF / Word
Evidence Gap Analysis
Structured report ranking evidence gaps by strategic priority with recommendations for clinical study design.
PDF / Word
Regulatory Submission Summary
Concise clinical evidence narrative for FDA, EMA, or HTA dossier submissions with source citations.
WEB APP
HTA Intelligence Dashboard
Live dashboard tracking HTA decisions, payer positions, and reimbursement status across NICE, G-BA, HAS, ICER, CADTH, AIFA, AEM.
Word / PDF
Global Value Dossier
Structured dossier narrative -- clinical summary, PICOTS, economic model narrative, and appendices aligned to each HTA body template.
PowerPoint / PDF
Payer Objection Handler
Q&A document with anticipated payer objections and structured counterarguments on efficacy, durability, and pricing.
PDF / Word
Reimbursement Landscape Report
Multi-country reimbursement summary covering coverage, formulary placement, access restrictions, and price benchmarking.
PDF / Word
Payer Briefing Note
1-2 page briefing synthesizing clinical evidence, budget impact, and access context for field teams ahead of payer meetings.
Excel / Word
Country Adaptation Package
Localized model and narrative adapted to country-specific epidemiology, unit costs, comparators, and HTA methodology.
WHY VALUEGEN.AI
What Sets ValueGen.AI Apart
Domain-Built, Not Generic
Trained and optimized for HEOR and market access -- not a general LLM wrapper. Natively understands HEOR methodologies, NICE appraisal logic, and CEA model structures.
Full Traceability
Every output includes source citations and evidence grounding. Outputs are auditable -- essential for regulatory submissions and payer negotiations.
Reliability Scoring
Proprietary framework flags outputs by evidence quality, novelty risk, and domain complexity -- telling users exactly when to trust vs. verify output.
Wide-Market Coverage
Natively processes HTA reports in French, German, Italian, Spanish, and English -- summarizing in English. Covers NICE, G-BA, HAS, ICER, CADTH, AIFA, AEM, and more.
Speed Advantage
Landscape assessments in 48 hours vs. months. Objection handlers in minutes. Frees senior experts for high-value strategic work that requires human judgment.
Enterprise-Grade Security
SSO/Auth0, role-based access control, TLS 1.2 encryption, data encrypted at rest. Client data is never used for model retraining or secondary purposes.
GET STARTED
Ready to Transform Your HEOR & Market Access Workflows?
ValueGen.AI replaces months of manual effort with AI-powered workflows that HEOR and market access professionals can trust and act on immediately.